Clinical trial
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies…
NCT00439556 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00439556 |
|---|---|
| Title | Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant |
| Official title | Bortezomib (Velcade®) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bortezomib, Carmustine, Cytarabine, Etoposide, Filgrastim, Melphalan, Methotrexate, Rituximab and 1 more |
| Enrollment | 40 |
| Start date | Feb 13, 2007 |
| Primary completion | Jun 7, 2018 |
| Completion | Jun 7, 2018 |
| First posted | Feb 23, 2007 |
| Last update posted | Sep 10, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: